Home » Stocks » DVA

DaVita Inc. (DVA)

Stock Price: $109.30 USD 3.88 (3.68%)
Updated December 4, 4:00 PM EST - Market closed

DVA Stock Price Chart

Key Info

Market Cap 12.24B
Revenue (ttm) 11.54B
Net Income (ttm) 844.74M
Shares Out 120.91M
EPS (ttm) 6.68
PE Ratio 16.36
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 4
Last Price $109.30
Previous Close $105.42
Change ($) 3.88
Change (%) 3.68%
Day's Open 106.08
Day's Range 106.00 - 109.30
Day's Volume 601,957
52-Week Range 64.99 - 113.39

DVA Stock News

Zacks Investment Research - 1 week ago

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to th...

Zacks Investment Research - 1 week ago

Is DaVita (DVA) a great pick from the value investor's perspective right now? Read on to know more.

Zacks Investment Research - 1 week ago

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider DaVita (DVA).

Zacks Investment Research - 1 week ago

As of late, it has definitely been a great time to be an investor in DaVita (DVA).

Zacks Investment Research - 1 week ago

DVA vs. CHE: Which Stock Is the Better Value Option?

Other stocks mentioned: CHE
PRNewsWire - 1 week ago

DENVER, Nov. 23, 2020 /PRNewswire/ -- DaVita Inc. today announced its annual cycling event, Tour DaVita, raised nearly $1 million to benefit Bridge of Life, a nonprofit founded by DaVita that ...

Zacks Investment Research - 2 weeks ago

Investor confidence is high on DaVita (DVA) stock, thanks to solid prospects.

Zacks Investment Research - 2 weeks ago

Is (DVA) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 3 weeks ago

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to th...

Insider Monkey - 3 weeks ago

Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another...

Zacks Investment Research - 4 weeks ago

DVA vs. CHE: Which Stock Is the Better Value Option?

Other stocks mentioned: CHE
PRNewsWire - 1 month ago

SACRAMENTO, Calif., Nov. 4, 2020 /PRNewswire/ -- DaVita Kidney Care, a leading provider of kidney care services in the United States, issued the following statement: "We are grateful that Cali...

Investors Business Daily - 1 month ago

Davita Healthcare Partners sees its Relative Strength Rating move into the 80-plus level. The post Davita Healthcare Partners Clears Key Benchmark, Hitting 80-Plus RS Rating appeared first on ...

Zacks Investment Research - 1 month ago

Investors target stocks that have been on a bullish run, lately. Stocks seeing price strength have higher chances of carrying the momentum ahead.

Other stocks mentioned: EAT, GPI, HMST, MMSI, OMI
Zacks Investment Research - 1 month ago

Rise in coronavirus cases and uncertainties revolving around the election might keep markets volatile for some time. Here are five stocks to invest in and play safe.

Other stocks mentioned: OMI, PRMW, SAM, UNFI
Zacks Investment Research - 1 month ago

DaVita (DVA) saw strength in dialysis services in the United States in the third quarter.

Seeking Alpha - 1 month ago

DaVita, Inc. (DVA) CEO Javier Rodriguez on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 1 month ago

DaVita HealthCare (DVA) delivered earnings and revenue surprises of 20.81% and -0.60%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the ...

PRNewsWire - 1 month ago

DENVER, Oct. 29, 2020 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the third quarter ended September 30, 2020. During the quarter, notwithstanding the ...

Zacks Investment Research - 1 month ago

Coronavirus is going to affect the earnings results of healthcare players. While hospitals and health insurers might have suffered the COVID-19 impact, others providing virtual care and COVID-...

Other stocks mentioned: CHE, CRL, NVCR, UHS
Zacks Investment Research - 1 month ago

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to th...

Zacks Investment Research - 1 month ago

Solid performance by the net dialysis and related lab patient service segment is likely to have contributed to DaVita's (DVA) top line in the third quarter.

Zacks Investment Research - 1 month ago

DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 month ago

Is (DVA) Outperforming Other Medical Stocks This Year?

PRNewsWire - 1 month ago

DENVER, Oct. 22, 2020 /PRNewswire/ -- DaVita Clinical Research (DCR) will present 14 research abstracts from company representatives and medical professionals at the American Society of Nephro...

The Motley Fool - 1 month ago

Many Warren Buffett stocks remain buys.

Other stocks mentioned: GOLD, STNE
PRNewsWire - 1 month ago

DENVER, Oct. 15, 2020 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss third quarter results on Thursday, October 29, 2020, a...

Zacks Investment Research - 1 month ago

DaVita HealthCare (DVA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research - 1 month ago

Grab these four stocks that continue to show tremendous promise despite market volatility resulting from the coronavirus pandemic.

Other stocks mentioned: LHCG, OMI, RMD
Seeking Alpha - 1 month ago

DaVita's business model is able to provide the company with very reliable and stable revenues, as patients need their dialysis treatment on a constant basis.

Zacks Investment Research - 1 month ago

These three MedTech stocks are expected to grow post their Q3 earnings release.

Other stocks mentioned: ARAY, CAH
Zacks Investment Research - 1 month ago

DVA vs. CHE: Which Stock Is the Better Value Option?

Other stocks mentioned: CHE
Zacks Investment Research - 2 months ago

These cheap MedTech stocks are currently flourishing on the back of a number of positive developments.

Other stocks mentioned: ANTM, NXGN
Zacks Investment Research - 2 months ago

This apparently simple-to-understand investing discipline has its own share of pitfalls.

Other stocks mentioned: BERY, GM, TGNA, WHR
GuruFocus - 2 months ago

With four potential Covid-19 vaccine candidates from Moderna Inc. (NASDAQ:MRNA), Pfizer Inc. (NYSE:PFE), AstraZeneca PLC (NYSE:AZN) and Johnson & Johnson (NYSE:JNJ) now in late-stage human tri...

Other stocks mentioned: BIO, MOH
Zacks Investment Research - 2 months ago

Backed by projections of robust earnings growth rates, there are a few MedTech stocks which are ideal for long-term bet.

Other stocks mentioned: MMSI, OPK
Zacks Investment Research - 2 months ago

DaVita (DVA) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.

Seeking Alpha - 2 months ago

With the market selling off hard and both economic and political uncertainty on the rise, many investors yearn to turn to the most trusted and respected investors in history.

Other stocks mentioned: BIIB, LSXMK, SIRI, STOR, BRK.A, BRK.B
GuruFocus - 2 months ago

Warren Buffett (Trades, Portfolio), head of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B), disclosed this week his firm reduced its stake in DaVita Inc.

Zacks Investment Research - 2 months ago

Market sentiment is down lately due to Fed's muted outlook and rising cases of coronavirus in Europe.

Other stocks mentioned: LEN, MAS, PCAR
Zacks Investment Research - 2 months ago

DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

PRNewsWire - 2 months ago

DENVER, Sept. 17, 2020 /PRNewswire/ -- DAVITA INC.

Zacks Investment Research - 2 months ago

Here are some dirt-cheap MedTech value stocks which have been battered by the pandemic-led market meltdown and can be considered for long-term gains.

Other stocks mentioned: AMN, FMS, NXGN
PRNewsWire - 2 months ago

DENVER, Sept. 15, 2020 /PRNewswire/ -- DAVITA INC.

Zacks Investment Research - 2 months ago

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have higher chances of carrying the momentum ahead.

Other stocks mentioned: EAT, PFSI, TGT, TPH
Zacks Investment Research - 2 months ago

We have highlighted some stock-picking ideas from the top-ranked cohort that could prove extremely beneficial for investors in the current market environment, reducing the risk of a downside.

Other stocks mentioned: BIG, RCII, SFM
Zacks Investment Research - 2 months ago

Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.

Other stocks mentioned: ABG, DKS, EXPD, HIBB
PRNewsWire - 2 months ago

DENVER, Sept. 8, 2020 /PRNewswire/ -- DaVita Inc.

Zacks Investment Research - 3 months ago

The S&P 500 posted its worst single-session drop in nearly three months mainly on profit booking. While high-flying tech names were hurt the most, laggards are better positioned.

Other stocks mentioned: GPI, GPK, JPM, UAL
Zacks Investment Research - 3 months ago

3 Top Outpatient and Home Healthcare Stocks to Watch Out For

Other stocks mentioned: PNTG, USPH

About DVA

DaVita provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In ad... [Read more...]

Industry
Medical Care Facilities
IPO Date
Oct 31, 1995
CEO
Javier Rodriguez
Employees
65,000
Stock Exchange
NYSE
Ticker Symbol
DVA
Full Company Profile

Financial Performance

In 2019, DaVita's revenue was $11.39 billion, a decrease of -0.14% compared to the previous year's $11.40 billion. Earnings were $810.98 million, an increase of 408.79%.

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for DaVita stock is "Hold." The 12-month stock price forecast is 102.70, which is a decrease of -6.04% from the latest price.

Price Target
$102.70
(-6.04% downside)
Analyst Consensus: Hold